Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Escherichia Coli Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of ETEC Vaccine

NCT01147445
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 1, 2026, 11:40 AM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 1, 2026, 11:40 AM EDT
Terminated Not applicable Interventional

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

NCT02882841
View directory record Official record
Conditions
Crohn's Disease
Interventions
Biopsies, stool and blood collection
Other
Lead sponsor
Enterome
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ETEC Logistics Trial (TREK)

NCT00516659
View directory record Official record
Conditions
Diarrhea
Interventions
Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
13
States / cities
Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 1, 2026, 11:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo, Bacteriophage preparation
Biological
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lutherville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 1, 2026, 11:40 AM EDT
Completed No phase listed Observational

Antibiotic Resistant Community-Acquired E. Coli

NCT00298103
View directory record Official record
Conditions
E Coli Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 1, 2026, 11:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

NCT03548064
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli, Immunisation
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 1, 2026, 11:40 AM EDT
Not yet recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections

NCT01776021
View directory record Official record
Conditions
Urinary Tract Infections, Infection, Urologic Diseases
Interventions
cranberry juice, placebo beverage
Other
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
17
States / cities
Chandler, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 1, 2026, 11:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

NCT04087681
View directory record Official record
Conditions
E.Coli Infections
Interventions
Not listed
Lead sponsor
MJM Bonten
Other
Eligibility
60 Years and older
Enrollment
4,479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

NCT03922061
View directory record Official record
Conditions
Polio
Interventions
dmLT, fIPV
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 1, 2026, 11:40 AM EDT
Completed No phase listed Observational

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

NCT00915213
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Irvine, California • Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 1, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Sublingual dmLT for ETEC

NCT02052934
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 1, 2026, 11:40 AM EDT